Select Language
COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hospital Acquired Disease Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Indication
5.5 Market Breakup by Region
5.6 Market Forecast
5.7 SWOT Analysis
5.7.1 Overview
5.7.2 Strengths
5.7.3 Weaknesses
5.7.4 Opportunities
5.7.5 Threats
5.8 Value Chain Analysis
5.9 Porters Five Forces Analysis
5.9.1 Overview
5.9.2 Bargaining Power of Buyers
5.9.3 Bargaining Power of Suppliers
5.9.4 Degree of Competition
5.9.5 Threat of New Entrants
5.9.6 Threat of Substitutes
5.10 Price Analysis
6 Market Breakup by Indication
6.1 UTI (Urinary Tract Infection)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 SSI (Surgical Site Infection)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Pneumonia
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Bloodstream Infections
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Region
7.1 North America
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Europe
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Asia Pacific
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Middle East and Africa
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Latin America
7.5.1 Market Trends
7.5.2 Market Forecast
8 Competitive Landscape
8.1 Market Structure
8.2 Key Players
8.3 Profiles of Key Players
8.3.1 Abbott Laboratories
8.3.2 Alere, Inc.
8.3.3 Becton, Dickinson and Company
8.3.4 bioMérieux SA
8.3.5 F. Hoffmann-La Roche Ltd.
8.3.6 Hologic, Inc.
8.3.7 QIAGEN
8.3.8 Siemens Healthcare
8.3.9 Diatherix Laboratories, Inc.
8.3.10 Meridian Bioscience, Inc.
8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
8.3.12 Cepheid, Inc.
List of Figures
Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2020
Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2020
Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
Figure 7: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
List of Tables
Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2021-2026
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players
The global hospital acquired disease testing market size was valued at US$ 7.32 Billion in 2020.
According to the estimates by IMARC Group, the global hospital acquired disease testing market is expected to exhibit strong growth during 2021-2026.
Rising incidences of HAIs upon exposure to infected patients, contaminated linens, medical equipment, etc., are currently driving the market for hospital acquired disease testing.
Several technological advancements have led to the introduction of microarrays, solid phase hybridization, polymerase chain reaction (PCR) and real-time location systems (RTLSs) for detecting and monitoring HAIs, thereby representing the one of the key trends in the global hospital acquired disease testing market.
Sudden outbreak of the COVID-19 pandemic has led to the rising demand for advanced and effective testing devices for hospital acquired diseases based on the increasing risk of coronavirus contraction upon hospital visits.
On the basis of the indication, the market has been bifurcated into urinary tract infection, surgical site infection (SSI), pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus (MRSA), and others. Amongst these, urinary tract infection (UTI) holds the majority of the total market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global hospital acquired disease testing market are Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
10% Free customization
Purchase Options
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at
sales@imarcgroup.com